The U.S. Food and Drug Administration approved Deciphera Pharmaceuticals Inc.’s Qinlock (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

AstraZeneca and Merck & Co. announced that the U.S. Food and Drug Administration approved the kinase inhibitor Koselugo (selumetinib) for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas.

Merck & Co. Inc. is buying ArQule Inc. for $2.7 billion, seeking to tap into the drug developer’s experimental blood cancer therapy that targets genetic mutations.

AstraZeneca is significantly expanding the company’s footprint in China with the establishment of a global R&D center and launch of a $1 billion fund aimed at supporting that nation’s healthcare sector.

Bayer, Bristol-Myers Squibb and Ono Pharmaceutical teamed up to study the most common type of metastatic colorectal cancer.

Clinical-stage immuno-oncology company Forty Seven Inc. announced a collaboration with Acerta Pharma, AstraZeneca’s hematology research and development center of excellence.

Indianapolis-based Eli Lilly continues to make the case for cyclin-dependent kinases inhibitors, particularly CDK4 and CDK6, as an effective treatment of cancers.

Flexion Therapeutics scrapped an eight-year-old agreement with pharma giant AstraZeneca to develop an end-stage osteoarthritis treatment.

After a former Pfizer employee’s publications came under question, the company launched a review of Min-Jean Yin’s publication history and pushed for two additional retractions.

Dermatologic-focused Aclaris Therapeutics Inc. is expanding its pipeline into new territory with the acquisition of Missouri-based Confluence Life Sciences Inc., a seven-year-old privately held startup focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.